Overview

  • Product name
    Recombinant human WISP3 protein
  • Protein length
    Full length protein

Description

  • Nature
    Recombinant
  • Source
    Escherichia coli
  • Amino Acid Sequence
    • Species
      Human
    • Sequence
      TGPLDTTPEG RPGEVSDAPQ RKQFCHWPCK CPQQKPRCPP GVSLVRDGCG CCKICAKQPG EICNEADLCD PHKGLYCDYS VDRPRYETGV CAYLVAVGCE FNQVHYHNGQ VFQPNPLFSC LCVSGAIGCT PLFIPKLAGS HCSGAKGGKK SDQSNCSLEP LLQQLSTSYK TMPAYRNLPL IWKKKCLVQA TKWTPCSRTC GMGISNRVTN ENSNCEMRKE KRLCYIQPCD SNILKTIKIP KGKTCQPTFQ LSKAEKFVFS GCSSTQSYKP TFCGICLDKR CCIPNKSKMI TIQFDCPNEG SFKWKMLWIT SCVCQRNCRE PGDIFSELKI L

Associated products

Specifications

Our Abpromise guarantee covers the use of ab50049 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Biological activity
    Biological Activity : The ED50 was determined by the dose-dependant proliferation of the MCF-7 cell line. The expected ED50 for this effect is 0.2-0.3 µg/ml.
  • Applications

    SDS-PAGE

    Functional Studies

  • Endotoxin level
    < 0.100 Eu/µg
  • Form
    Lyophilised
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. The lyophilized protein is stable for a few weeks at room temperature. Store at -20°C long term.

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

General Info

  • Alternative names
    • CCN 6
    • CCN family member 6
    • CCN6
    • CYR61
    • LIBC
    • Lost in inflammatory breast cancer tumor suppressor protein
    • MGC125987
    • MGC125988
    • MGC125989
    • OTTHUMP00000040421
    • PPAC
    • PPD
    • UNQ462/PRO790/PRO956
    • WISP 3
    • WISP-3
    • WISP3
    • WISP3_HUMAN
    • WNT 1 inducible signaling pathway protein 3
    • Wnt 1 signaling pathway protein 3
    • WNT1 inducible signaling pathway protein 3
    • WNT1 inducible signaling pathway protein 3 precursor
    • WNT1-inducible-signaling pathway protein 3
    see all
  • Function
    Appears to be required for normal postnatal skeletal growth and cartilage homeostasis.
  • Tissue specificity
    Predominant expression in adult kidney and testis and fetal kidney. Weaker expression found in placenta, ovary, prostate and small intestine. Also expressed in skeletally-derived cells such as synoviocytes and articular cartilage chondrocytes.
  • Involvement in disease
    Defects in WISP3 are the cause of progressive pseudorheumatoid arthropathy of childhood (PPAC) [MIM:208230]. PPAC is an autosomal recessive disorder characterized by stiffness and swelling of joints, motor weakness and joint contractures. Signs and symptoms of the disease develop typically between three and eight years of age. This progressive disease is a primary disorder of articular cartilage with continued cartilage loss and destructive bone changes with aging.
  • Sequence similarities
    Belongs to the CCN family.
    Contains 1 CTCK (C-terminal cystine knot-like) domain.
    Contains 1 IGFBP N-terminal domain.
    Contains 1 TSP type-1 domain.
  • Cellular localization
    Secreted.
  • Information by UniProt

References

ab50049 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

Answer

Thank you for your telephone enquiry yesterday afternoon. I can confirm that our ab50049 WISP3 human protein (Active) has been tested for biological activity in cell culture, so it will be covered by our guarantee for this application. The originator of the protein has kindly provided the following information which I hope you will find helpful: The ED50 was determined by the dose-dependent proliferation of the MCF-7 cell line. The expected ED50 for this effect is 0.2-0.3 µg/ml. The protocol used was as follows: Note: As of lot 020405 culture and assay media have been changed to media containing no phenol red. Also the cells are cultured in 10% Certified FBS, but the assay media contains 0.25% HI-FBS. 1. Resuspend cells in assay media containing 0.25% HI-FBS Transfer 100ul culture/well to assay plate (5,000 cells/well; passage 22). 2. Serial dilute h-WISP-3 in assay media in duplicate. 3. Add 100ul/well of h-WISP-3 to cells in assay plate. Final assay volume is 200ul/well containing 0.25% HI-FBS, and h-WISP-3. 4. Incubate 90 hours. 5. Add 20ul of Substrate Cell Titer Aqueous One Solution Reagent to each well. 6. Incubate 37oC and read OC at 490nm. The endotoxin level was tested for this and was found to be less than 0.1 ng per µg (1EU/µg). I hope this information is useful to you. Please do not hesitate to contact us should you have any additional questions.

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up